Ogivri: Withdrawal of the marketing authorisation application

Overview

On 3 August 2017, Mylan S.A.S. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Ogivri, for the treatment of breast cancer and gastric cancer.

  • List item

    Questions and answers on the withdrawal of the marketing authorisation application for Ogivri (trastuzumab) (PDF/68.17 KB)


    First published: 15/09/2017
    Last updated: 15/09/2017
    EMA/564631/2017

  • Key facts

    Name
    Ogivri
    Product number
    EMEA/H/C/004346
    Date of withdrawal
    03/08/2017
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating
    Average
    1 rating
    1 rating